Search results for "Metas"

showing 10 items of 1693 documents

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor s…

1997

Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressively escalated by 2 mg/m2/cycle up to 18 mg/m2 in the absence of dose-limiting toxicities. Granulocyte colony stimulating factor (G-CSF) was given s.c. in order to prevent neutropenia. DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significa…

AdultAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentAntidotesLeucovorinAntineoplastic AgentsBreast NeoplasmsPharmacologyNeutropeniaGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicinePharmacology (medical)Antineoplastic Agents AlkylatingCyclophosphamideAgedPharmacologyMitoxantroneChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerGranulocyte colony-stimulating factorItalyOncologyToxicityAbsolute neutrophil countFemaleFluorouracilMitoxantronebusinessmedicine.drugAnti-Cancer Drugs
researchProduct

The utility of 3D medical imaging techniques for obtaining a reliable differential diagnosis of metastatic cancer in an Iron Age skull.

2018

Abstract In this report we present a case of neoplastic disease affecting an Iron Age skull that provides some of the earliest evidence of metastatic cancer (MC) in Western Europe. The cranium comes from the indigenous site of Baucina (Palermo, Sicily) and was recovered in a multiple burial context dated to the 6th–5th centuries BCE. The skull was attributed to an adult female and was characterized by numerous perforating lytic lesions. CT and 3D imaging analyses were crucial for obtaining a diagnosis of MC. Based on the morphology of the lytic lesions and the biological profile of our specimen, we can tentatively suggest breast carcinoma as the primary origin of the clinical manifestations…

AdultArcheologyPathologymedicine.medical_specialtyPaleopathologyPalaeopathology Osteolytic lesions 3D imaging Differential diagnosis Metastatic carcinomaContext (language use)Bone NeoplasmsSettore BIO/08 - Antropologia030218 nuclear medicine & medical imagingPathology and Forensic MedicineMetastatic carcinomaDiagnosis Differential03 medical and health sciences0302 clinical medicineImaging Three-DimensionalImage Interpretation Computer-AssistedMedical imagingmedicineHumans0601 history and archaeologyNeoplasm MetastasisPaleopathologyHistory Ancient060101 anthropologybusiness.industryFossilsCarcinomaSkullCancer06 humanities and the artsmedicine.diseaseSkullmedicine.anatomical_structureFemaleDifferential diagnosisBreast carcinomabusinessTomography X-Ray ComputedInternational journal of paleopathology
researchProduct

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.

2008

AIMS: CD1a is a molecule belonging to the highly conserved group of CD1 proteins. Its expression in dendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently, the development of a successful antitumour response. The aim was to investigate the presence of CD1a+ cells in both primary tumours and lymph nodes (LN) of a series of 35 invasive ductal carcinomas by both immunohistochemistry and reverse transcription-polymerase chain reaction. METHODS AND RESULTS: CD1a antigen was more expressed in N0 than N1 breast cancer (P < 0.0001) in both primary lesions and LN metastases and correlated positively and significantly with oestrogen (ER) (P =…

AdultCD4-Positive T-LymphocytesCarcinoma Ductal BreastDown-RegulationBreast NeoplasmsDendritic CellsCD8-Positive T-LymphocytesMiddle AgedCD1APrognosisImmunohistochemistryAntigens CD1Gene Expression Regulation NeoplasticReceptors EstrogenPredictive Value of TestsLymphatic MetastasisHumansFemaleReceptors ProgesteroneAged
researchProduct

Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer

2014

Abstract There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copy-number alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered “actionable.” Alterations…

AdultCancer ResearchARID1AConcordanceBreast NeoplasmsGenomicsArticleExonBreast cancermedicineCluster AnalysisHumansPTENNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overbiologyGene Expression ProfilingPoint mutationGenomicsMiddle Agedmedicine.diseaseGene Expression Regulation NeoplasticGene expression profilingOncologyMutationbiology.proteinCancer researchFemaleNeoplasm Recurrence LocalMolecular Cancer Therapeutics
researchProduct

Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance.

2000

The metabolic microenvironment of a tumor is predominantly determined by the efficacy of blood flow, flux parameters (such as diffusion and convective currents in the interstitial space) and metabolic rates. The most important factors in this context include oxygen and nutrient supply, tissue pH and the bioenergetic status. It is now widely accepted that the metabolic microenvironment of a tumor can dramatically influence a range of factors such as proliferation rate, cell cycle position, growth rate and the development of apoptosis and necrosis. At the same time, these parameters can have an impact on tumor detection, therapeutic response to conventional irradiation, some chemotherapy agen…

AdultCancer ResearchMammary glandAntineoplastic AgentsBreast NeoplasmsBiologyRadiation ToleranceMetastasisMicrocirculationOxygen ConsumptionInterstitial spacemedicinePressureHumansAgedOncogeneNeovascularization PathologicMicrocirculationCancerCell cycleHydrogen-Ion ConcentrationMiddle Agedmedicine.diseaseMolecular medicineCell HypoxiaBody FluidsOxygenmedicine.anatomical_structureOncologyImmunologyCancer researchFemaleMenopauseEnergy MetabolismBlood Flow VelocityCell DivisionInternational journal of oncology
researchProduct

Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis.

2006

The recurrence of pleural effusions is a common event in a variety of neoplastic diseases. The objective of this study was to identify the mechanisms promoting the homing and growth of cancer cells within the pleural space. A cancer cell line recovered from malignant pleural fluids (lung adenocarcinoma cell line) that constitutively expresses cyclooxygenase 2 (COX-2) and all types of prostaglandin receptors was studied. It was first demonstrated using a matrigel system, that malignant pleural fluids increase the invasiveness of adenocarcinoma cells more than congestive heart failure (CHF) pleural fluids. Moreover, exposure to exudative malignant, but not to CHF pleural fluids, increased the…

AdultCancer ResearchPathologymedicine.medical_specialtyLung NeoplasmsPleural effusionAdenocarcinomaDinoprostoneMetastasisCell Line TumormedicineHumansReceptors Prostaglandin ENeoplasm InvasivenessProstaglandin E2PleurisyAgedCell ProliferationMatrigelCyclooxygenase 2 Inhibitorsbusiness.industryNF-kappa BCancerMiddle Agedmedicine.diseaseNeoplasm ProteinsPleural Effusion MalignantUp-RegulationOncologyPleurisyCyclooxygenase 2TalcCancer cellAdenocarcinomabusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Multidirectional differentiation in a newly established human epithelioid sarcoma cell line (GRU-1) with co-expression of vimentin, cytokeratins and …

1990

A new permanent cell line (GRU-1) derived from the lymph-node metastasis of a human epithelioid sarcoma was established in tissue culture. Immunohistochemically, the original tumor had exhibited an intriguing potential for multidirectional differentiation with features of mesenchymal, epithelial and neural differentiation, evidenced by the co-expression of vimentin, cytokeratins and neurofilament proteins, respectively. This capability for multidirectional differentiation was fully preserved in the cultured cells. GRU-1 tumor cells proved to be uniformly positive for vimentin and a considerable proportion of the tumor cells exhibited a positive reaction for cytokeratins and neurofilament pr…

AdultCancer ResearchPathologymedicine.medical_specialtyNeurofilamentEpithelioid sarcomaMice NudeVimentinCell LineCytokeratinMiceIntermediate Filament ProteinsNeurofilament ProteinsmedicineTumor Cells CulturedAnimalsHumansVimentinbiologyMesenchymal stem cellSarcomaDNA Neoplasmmedicine.diseaseFlow CytometryImmunohistochemistryGene Expression Regulation NeoplasticMicroscopy ElectronCell Transformation NeoplasticOncologyCell cultureLymphatic Metastasisbiology.proteinSynaptophysinKeratinsFemaleSarcomaNeoplasm TransplantationInternational journal of cancer
researchProduct

Validity of Laparoscopic Staging to Avoid Adjuvant Chemoradiation following Radical Surgery in Patients with Early Cervical Cancer

2012

&lt;b&gt;&lt;i&gt;Purpose:&lt;/i&gt;&lt;/b&gt; To determine the rate of unavoidable adjuvant chemoradiation (RCTX) due to histologic results after radical surgery in patients with early cervical cancer. &lt;b&gt;&lt;i&gt;Patients and Methods:&lt;/i&gt;&lt;/b&gt; Between May 2004 and July 2011, 448 consecutive patients diagnosed with invasive cervical cancer stage IA1 L1 to IIA underwent laparoscopic staging at the Department of Gynecology and Gynecologic Oncology at Charité Berlin. Only in patients without lymph node metastases (n = 394) on frozen section, radical operation was continued either by laparoscopic radical hysterectomy (n = 228) or by radical vaginal trachelectomy (n = 166). The…

AdultCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentUterine Cervical NeoplasmsRadical vaginal trachelectomyAdjuvant chemoradiationHysterectomyYoung AdultRisk FactorsEarly cervical cancermedicineHumansRadical hysterectomyProspective StudiesRadical HysterectomyRadical surgeryLaparoscopyProspective cohort studyAgedNeoplasm StagingAged 80 and overCervical cancerHysterectomymedicine.diagnostic_testbusiness.industryGeneral surgeryChemoradiotherapy AdjuvantGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryClinical trialOncologyLymphatic MetastasisAdjuvant chemoradiation; Early cervical cancer; Radical hysterectomyVaginaLymph Node ExcisionFemaleLaparoscopyRisk factorbusinessChemoradiotherapy
researchProduct

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

2011

Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a central laboratory for both primary tumors and metastases. PTEN levels were assessed by IHC and phosphoinositide 3-kinase (PI3K) pathway mutations were detected by a mass spectroscopy–based approach. Median age was 48 years (range: 30–83 years). Tumor subtype included 72% horm…

AdultCancer Researchmedicine.medical_specialtyClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Breast Neoplasmsmedicine.disease_causeArticleMetastasisMetastasisPhosphatidylinositol 3-KinasesBreast cancerInternal medicineBreast CancermedicinePTENHumansPTEN lossReceptorneoplasmsPI3K/AKT/mTOR pathwayAgedAged 80 and overMutationbiologyPTEN PhosphohydrolaseMiddle Agedmedicine.diseaseMetastatic breast cancerEndocrinologyOncologyReceptors EstrogenMutationbiology.proteinCancer researchImmunohistochemistryFemalePIK3CA mutationsReceptors ProgesteroneSignal TransductionMolecular cancer therapeutics
researchProduct

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as …

2005

The sequential doxorubicin → CMF (CMF = cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to CMF in a randomised trial. The role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were randomised to: (a) CMF × 6 cycles (CMF); (b) doxorubicin × 4 cycles followed by CMF × 6 cycles (A → CMF); (c) CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (CMF → GT); and (d) doxorubicin × 4 cycles followed by CMF × 6 cycles followed by goserelin plus tamoxifen × 2 years (A → CMF → GT). The study used a 2 × 2 factorial experimental design to assess: (1) the effect of the chemotherapy regimens (CMF vs A …

AdultCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentUrologyBreast NeoplasmsDisease-Free SurvivalDrug Administration Schedulebreast cancerchemoendocrine treatmentAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineAdjuvant therapyHumansDoxorubicinCyclophosphamideanthracyclinesGynecologyChemotherapypremenopausalbusiness.industryGoserelinadjuvant therapyMiddle AgedCombined Modality TherapyTamoxifenRegimenMethotrexateOncologyChemotherapy AdjuvantDoxorubicinFluorouracilLymphatic MetastasisGoserelinFemaleFluorouracilbusinessTamoxifenFollow-Up Studiesmedicine.drugBritish Journal of Cancer
researchProduct